IMDX$2.83-1.05%
Insight Molecular Diagnostics Inc.
Sector: In Vitro & In Vivo Diagnostic SubstancesIndustry: Medical - Diagnostics & ResearchCountry: USExchange: Nasdaq
Mkt Cap:$92.61M
Float & O/S:
Inst Own:
DilutionScan read 37 of Insight Molecular Diagnostics Inc.'s SEC filings and found 10 warrant series, 1 convertible, 2 ATM programs, 3 shelf registrations, 1 S-1 registration and 1 completed offering on file for IMDX. The latest dilution event on file is an offering on Feb 12, 2026. Analysis updated Nov 1, 2026.
Signal8 Summary
IMDX
Cash-strapped, heavily diluting micro-cap
Snapshot
iMDx is a tiny diagnostics company still pre-commercial scale, with FY 2025 revenue of just $4.1M despite doubling YoY, and a net loss of $50.2M.
What's Happening Right Now
- : IMDX reported Q2 2026 results with a net loss of $11.3 million, alongside timely progress on FDA review of its GraftAssureDx kidney-transplant test.
- : iMDx filed to register 1.75 million more shares under its equity incentive plan, worth up to about $8.26 million.
- : A Lancet Regional Health study highlighted iMDx's GraftAssure assay for guiding kidney transplant drug treatment, alongside confirmed Medicare reimbursement for treatment-response monitoring.
- : A new Medicare policy expands coverage and allowed testing frequency for iMDx's dd-cfDNA GraftAssure assay portfolio, supporting commercial adoption.
- : A published study showed iMDx's GraftAssure CM-score outperforming standard tests for detecting kidney transplant rejection, supporting its pending FDA marketing application.
